• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Axcelis Technologies Inc.

    8/14/25 8:56:38 AM ET
    $ACLS
    Industrial Machinery/Components
    Technology
    Get the next $ACLS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Axcelis Technologies, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    054540208

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    054540208


    1Names of Reporting Persons

    American Century Investment Management, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,606,928.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,659,463.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,659,463.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    054540208


    1Names of Reporting Persons

    American Century Companies, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,606,928.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,659,463.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,659,463.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    054540208


    1Names of Reporting Persons

    Stowers Institute for Medical Research
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,606,928.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,659,463.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,659,463.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Axcelis Technologies, Inc.
    (b)Address of issuer's principal executive offices:

    108 Cherry Hill Drive, Beverly, MA, 01915
    Item 2. 
    (a)Name of person filing:

    American Century Investment Management, Inc. American Century Companies, Inc. Stowers Institute for Medical Research
    (b)Address or principal business office or, if none, residence:

    4500 Main Street 9th Floor Kansas City, Missouri 64111
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    054540208
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the response(s) to Item 9 on the attached cover page(s).
    (b)Percent of class:

    See the response(s) to Item 11 on the attached cover page(s).
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See the response(s) to Item 5 on the attached cover page(s).

     (ii) Shared power to vote or to direct the vote:

    See the response(s) to Item 6 on the attached cover page(s).

     (iii) Sole power to dispose or to direct the disposition of:

    See the response(s) to Item 7 on the attached cover page(s).

     (iv) Shared power to dispose or to direct the disposition of:

    See the response(s) to Item 8 on the attached cover page(s).

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Various persons, including the investment companies and separate institutional investor accounts that American Century Investment Management, Inc. ("ACIM") serves as investment adviser, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities that are the subject of this schedule. Except as may be otherwise indicated if this is a joint filing, not more than 5% of the class of securities that is the subject of this schedule is owned by any one client advised by ACIM.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    This Item identifies each subsidiary of American Century Companies, Inc. ("ACC"), which is controlled by the Stowers Institute for Medical Research, that is a beneficial owner of securities that are subject of this schedule (the "Subject Securities"). American Century Investment Management, Inc. ("ACIM") is a wholly-owned subsidiary of ACC and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940.
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    Not applicable
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    Not applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    American Century Investment Management, Inc.
     
    Signature:American Century Investment Management, Inc.
    Name/Title:/s/ John Pak / Senior Vice President
    Date:08/14/2025
     
    American Century Companies, Inc.
     
    Signature:American Century Companies, Inc.
    Name/Title:/s/ John Pak / Senior Vice President
    Date:08/14/2025
     
    Stowers Institute for Medical Research
     
    Signature:Stowers Institute for Medical Research
    Name/Title:/s/ Joselyn Verschelden / Authorized Signer
    Date:08/14/2025
    Exhibit Information

    EXHIBIT Each of the undersigned hereby agrees and consents to the execution and joint filing on its behalf by American Century Investment Management, Inc. of this Schedule 13G respecting the beneficial ownership of the securities which are the subject of this schedule. Dated this 14th day of August, 2025. AMERICAN CENTURY INVESTMENT MANAGEMENT, INC. ("ACIM") AMERICAN CENTURY COMPANIES, INC. ("ACC") By: __/s/ John Pak________ John Pak Senior Vice President, ACIM and ACC STOWERS INSTITUTE FOR MEDICAL RESEARCH, solely in its capacity as control entity of ACC By: __/s/ Joselyn Verschelden_____ Joselyn Verschelden Authorized Signer

    Get the next $ACLS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACLS

    DatePrice TargetRatingAnalyst
    4/21/2025$50.00Buy → Neutral
    B. Riley Securities
    2/12/2025Outperform → Mkt Perform
    William Blair
    11/8/2024Buy → Hold
    The Benchmark Company
    5/3/2024$130.00Hold → Buy
    Craig Hallum
    12/15/2023Buy → Neutral
    BofA Securities
    9/15/2023$225.00Buy
    BofA Securities
    8/4/2023$140.00 → $175.00Buy → Hold
    Craig Hallum
    6/14/2023Buy → Hold
    Needham
    More analyst ratings

    $ACLS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Axcelis Announces Joint Development Program with GE Aerospace For the Development of High Voltage Superjunction Power Devices

    BEVERLY, Mass., Aug. 20, 2025 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ:ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced a Joint Development Program (JDP) with GE Aerospace focused on the development of production-worthy 6.5 to 10kV superjunction power devices. Processes will be developed on Axcelis' Purion XEmax™ high energy implanter, which provides the industry's highest beam currents over the broadest energy range — up to 15MeV. This JDP supports the 'Advanced High Voltage Silicon Carbide Switches' project

    8/20/25 8:00:00 AM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    Axcelis Announces Financial Results for Second Quarter 2025

    Q2 Highlights: Revenue of $194.5 millionGAAP Gross Margin of 44.9%, and Non-GAAP Gross Margin of 45.2%GAAP Operating Margin of 14.9% and Non-GAAP Operating Margin of 17.7%GAAP Diluted earnings per share of $0.98, and Non-GAAP Diluted earnings per share of $1.13BEVERLY, Mass., Aug. 5, 2025 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ:ACLS) today announced financial results for the second quarter ended June 30, 2025. President and CEO Russell Low commented, "Axcelis delivered strong results in the second quarter despite the cyclical digestion period in many of our markets,

    8/5/25 7:00:00 AM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    Axcelis Announces Participation in Upcoming Investor Conferences in August

    BEVERLY, Mass., July 29, 2025 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ:ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced the company's plans to participate in the following upcoming investor conferences in August: The KBCM Technology Leadership Forum on Monday, August 11th at the Montage Deer Valley, Park City, UT.The Jefferies Semiconductor, IT Hardware and Communications Technology Conference on Tuesday, August 26th at the Four Seasons Hotel, Chicago, IL.The Evercore ISI 2025 Semiconductor, IT Hardware & Netw

    7/29/25 8:00:00 AM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    $ACLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Axcelis Tech downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded Axcelis Tech from Buy to Neutral and set a new price target of $50.00

    4/21/25 8:31:51 AM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    Axcelis Tech downgraded by William Blair

    William Blair downgraded Axcelis Tech from Outperform to Mkt Perform

    2/12/25 6:59:21 AM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    Axcelis Tech downgraded by The Benchmark Company

    The Benchmark Company downgraded Axcelis Tech from Buy to Hold

    11/8/24 7:32:05 AM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    $ACLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP MARKETING AND APPLICATIONS Redinbo Greg covered exercise/tax liability with 734 shares, decreasing direct ownership by 2% to 32,869 units (SEC Form 4)

    4 - AXCELIS TECHNOLOGIES INC (0001113232) (Issuer)

    6/17/25 5:05:07 PM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    EVP, Research, Dev. & Eng. Blumenstock Gerald M covered exercise/tax liability with 506 shares, decreasing direct ownership by 2% to 21,695 units (SEC Form 4)

    4 - AXCELIS TECHNOLOGIES INC (0001113232) (Issuer)

    6/17/25 5:05:10 PM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    Director Kurtzweil John T sold $104,166 worth of shares (1,682 units at $61.93), decreasing direct ownership by 5% to 35,050 units (SEC Form 4)

    4 - AXCELIS TECHNOLOGIES INC (0001113232) (Issuer)

    5/21/25 5:05:08 PM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    $ACLS
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Axcelis Technologies Inc.

    SCHEDULE 13G - AXCELIS TECHNOLOGIES INC (0001113232) (Subject)

    8/14/25 8:56:38 AM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    SEC Form 10-Q filed by Axcelis Technologies Inc.

    10-Q - AXCELIS TECHNOLOGIES INC (0001113232) (Filer)

    8/5/25 5:19:01 PM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    Axcelis Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AXCELIS TECHNOLOGIES INC (0001113232) (Filer)

    8/5/25 8:43:27 AM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    $ACLS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Low Russell bought $49,452 worth of shares (440 units at $112.39), increasing direct ownership by 0.77% to 57,754 units (SEC Form 4)

    4 - AXCELIS TECHNOLOGIES INC (0001113232) (Issuer)

    3/11/24 4:15:28 PM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    Coogan James Gordon bought $11,223 worth of shares (100 units at $112.23), increasing direct ownership by 2% to 5,991 units (SEC Form 4)

    4 - AXCELIS TECHNOLOGIES INC (0001113232) (Issuer)

    2/29/24 4:15:26 PM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    Lawson Douglas A. bought $55,520 worth of shares (500 units at $111.04), increasing direct ownership by 3% to 19,648 units (SEC Form 4)

    4 - AXCELIS TECHNOLOGIES INC (0001113232) (Issuer)

    2/26/24 8:15:07 AM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    $ACLS
    Financials

    Live finance-specific insights

    View All

    $ACLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $ACLS
    Leadership Updates

    Live Leadership Updates

    View All

    Axcelis Announces Financial Results for Second Quarter 2025

    Q2 Highlights: Revenue of $194.5 millionGAAP Gross Margin of 44.9%, and Non-GAAP Gross Margin of 45.2%GAAP Operating Margin of 14.9% and Non-GAAP Operating Margin of 17.7%GAAP Diluted earnings per share of $0.98, and Non-GAAP Diluted earnings per share of $1.13BEVERLY, Mass., Aug. 5, 2025 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ:ACLS) today announced financial results for the second quarter ended June 30, 2025. President and CEO Russell Low commented, "Axcelis delivered strong results in the second quarter despite the cyclical digestion period in many of our markets,

    8/5/25 7:00:00 AM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    Axcelis Announces Timing and Availability of Second Quarter 2025 Results and Conference Call

    BEVERLY, Mass., July 17, 2025 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ:ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry will release financial results for the second quarter 2025 before the opening of the market on Tuesday, August 5, 2025. The Company will host a call the same day to discuss the results at 8:30 a.m. ET. The call will be available via webcast that can be accessed through the Investors page of Axcelis' website at www.axcelis.com, or by registering as a participant here:https://register-conf.media-server.co

    7/17/25 8:00:00 AM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    Axcelis Announces Financial Results for First Quarter 2025

    Q1 Highlights: Revenue of $192.6 millionGAAP Gross Margin of 46.1%, and Non-GAAP Gross Margin of 46.4%GAAP Operating Margin of 15.1% and Non-GAAP Operating Margin of 18.3%GAAP Diluted earnings per share of $0.88, and Non-GAAP Diluted earnings per share of $1.04BEVERLY, Mass., May 6, 2025 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ:ACLS) today announced financial results for the first quarter ended March 31, 2025. President and CEO Russell Low commented, "We executed well in the first quarter, delivering strong profitability despite a moderation in customer investments a

    5/6/25 7:00:00 AM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    Amendment: SEC Form SC 13G/A filed by Axcelis Technologies Inc.

    SC 13G/A - AXCELIS TECHNOLOGIES INC (0001113232) (Subject)

    11/8/24 2:17:22 PM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    SEC Form SC 13G/A filed by Axcelis Technologies Inc. (Amendment)

    SC 13G/A - AXCELIS TECHNOLOGIES INC (0001113232) (Subject)

    2/13/24 4:58:56 PM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    SEC Form SC 13G/A filed by Axcelis Technologies Inc. (Amendment)

    SC 13G/A - AXCELIS TECHNOLOGIES INC (0001113232) (Subject)

    2/9/24 4:18:00 PM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    Axcelis Technologies Appoints David Ryzhik Senior Vice President of Investor Relations and Corporate Strategy

    The Company Announces Planned Retirement of Doug Lawson, Executive Vice President of Corporate Marketing and Strategy BEVERLY, Mass., June 27, 2024 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ:ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, today named David Ryzhik as Senior Vice President of Investor Relations and Corporate Strategy, assuming responsibility for the role in July 2024. The Company also announced the retirement of Doug Lawson, Executive Vice President of Corporate Marketing and Strategy. Mr. Lawson plans to retire in July 2024 and will remain as a Senior Advisor through July 2025.

    6/27/24 4:01:00 PM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    Axcelis Announces Shipment of 'Purion EXE SiC Power Series' Implanter and Successful 'Purion H200 SiC Power Series' Eval Closure at Leading Power Device Manufacturers in Japan

    BEVERLY, Mass., April 2, 2024 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ:ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced today a shipment of the Company's Purion EXE™ SiC high energy implanter as well as a successful Purion H200™ SiC medium energy implanter evaluation closure at leading power device chipmakers located in Japan. The systems will be used for 150mm and 200mm production of silicon carbide power devices supporting automotive, industrial, energy, and other power intensive applications. Greg Redinbo,

    4/2/24 8:00:00 AM ET
    $ACLS
    Industrial Machinery/Components
    Technology

    ClearPoint Neuro, Inc. Announces Appointment of Lynnette C. Fallon to Board of Directors

    SOLANA BEACH, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Lynnette C. Fallon has been appointed to the Company's Board of Directors effective immediately. Ms. Fallon will also become a member of the Company's Audit Committee. Ms. Fallon is the Executive Vice President, HR/Legal, General Counsel and Secretary of Axcelis Technologies, Inc. (NASDAQ:ACLS), a provider of equipment and service solutions for the semiconductor manufacturing industry, with locations in eight countries. Ms. Fallon has held her current position sin

    7/15/21 4:30:00 PM ET
    $CLPT
    $ACLS
    Medical/Dental Instruments
    Health Care
    Industrial Machinery/Components
    Technology